bikul das - Infectious Diseases

Author Information

Bikul Das is a prominent researcher affiliated with the KaviKrishna Laboratory at Guwahati Biotech Park, Indian Institute of Technology, Guwahati, India, and the Department of Immunity and Infectious Diseases at Forsyth Institute, Cambridge, Massachusetts. His work spans multiple areas of biomedical research, with a strong focus on stem cells, cancer therapy, and infectious diseases.

Research Contributions

Dr. Bikul Das has made significant contributions to the understanding of stem cell behavior and its implications in cancer and infectious diseases. His research includes exploring the roles of stem cells in tumorigenicity, cancer therapy, and immune responses. Notable works include studies on pathogen-induced stem cell niche defense, the enhancement of tumorigenicity in breast tumor spheroids, and the interaction between coronavirus and dormant tuberculosis. His innovative approaches often involve examining molecular pathways and potential therapies that could transform cancer treatment and immune modulation.

Aliases

No aliases have been provided in the author's profile.

Publication and Citation Metrics

Metric	Value
Total Papers	79
Total Citations	2837
H-index	20

Publications:

Targeting tumor stemness switch phenotype by activating pathogen induced stem cell niche defense

DOI: 10.1101/2022.03.25.485829

Year: 2022

3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model

DOI: 10.3390/cancers13112784

Year: 2021

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

DOI: 10.18632/oncotarget.28011

Year: 2021

Profiling transcription factor sub-networks in type I interferon signaling and in response to SARS-CoV-2 infection

DOI: 10.1515/cmb-2020-0128

Year: 2021

Regulation of early growth response-1 (Egr-1) gene expression by Stat1-independent type I interferon signaling and respiratory viruses

DOI: 10.1515/cmb-2020-0129

Year: 2021

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy

DOI: 10.3390/cancers13143596

Year: 2021

Coronavirus Activates an Altruistic Stem Cell–Mediated Defense Mechanism that Reactivates Dormant Tuberculosis

DOI: 10.1016/j.ajpath.2021.03.011

Year: 2021

Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells

DOI: 10.3389/fimmu.2020.594572

Year: 2020

Abstract 5539: Mesenchymal stem cell altruism mediates a novel HMGB1/NKG2D immune response in oral cancer

DOI: 10.1158/1538-7445.am2020-5539

Year: 2020

Abstract 487: Safety and functional profiling of clinical grade mesenchymal stem cells derived from bone marrow, adipose tissue and Wharton's jelly for cancer therapy

DOI: 10.1158/1538-7445.am2020-487

Year: 2020

Are There Any Emerging Technologies in Mosquito Control?

What is the DTaP Vaccine?

How Does Parasite DNA Contribute to Drug Resistance?

What is the Treatment for Gonorrhea?

What is Real-Time PCR?

What are the Safety Concerns with New Therapies?

What Diseases are Caused by Apicomplexan Parasites?

What Types of Surveillance Systems Exist?

What Guidelines Does the CDC Provide for Infectious Disease Prevention?

What Are the Treatment Options for Co-Infections?

Partnered Content Networks

Relevant Topics